Key result
Vaccination with a type 7 adenovirus-SV40 hybrid protected weanling hamsters against SV40-transformed cells, increasing the 50% tumor-inducing cell dose from <100 to >40,000 cells.
Why the study?
Does vaccination with an adenovirus-SV40 hybrid protect weanling hamsters against cells transformed by papovavirus SV40?
Population
Weanling hamsters
Comparison
Vaccination with type 7 adenovirus-SV40 "hybrid" vs SV40 vaccination, nonhybridized adenovirus type…
Design
Preclinical
Authors
Loading...
Extends hybrid-virus vaccine protection to SV40 models in hamsters; leaves open translation to human oncology.
Does vaccination with an adenovirus-SV40 hybrid protect weanling hamsters against cells transformed by papovavirus SV40?
Absolute Event Rate: 40000% vs 100%
The adenovirus-SV40 hybrid confers transplantation resistance against SV40-transformed cells in hamsters, similar to SV40 itself.
Rapp et al. (1966) studied Tumors induced by papovavirus SV40 transformed cells. Type 7 adenovirus-SV40 hybrid vaccine vs. Controls, SV40 vaccine, and nonhybridized adenovirus type 7 was evaluated on Number of cells required to induce tumors in 50 percent of the challenged animals. Vaccination with a type 7 adenovirus-SV40 hybrid protected weanling hamsters against SV40-transformed cells, increasing the 50% tumor-inducing cell dose from <100 to >40,000 cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: